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Abstract
Background: Patients with type 2 diabetes mellitus (T2DM) have accelerated atherosclerosis as a pro thrombotic
state that is associated with the platelet activation priming. Platelets, which undergo the continuous mild stimulation,
may lose their sensitivity to react to a strong stimulation. The present study aimed to investigate activation responses
of platelets to mild and subsequent strong stimulations in patients with T2DM and healthy individuals.
Methods: Blood samples, which were taken from 40 patients with T2DM and 35 healthy individuals, were collected
into the citrate containing tubes. The samples were subjected to the soft centrifugation to prepare the platelet rich
plasma (PRP). Platelets in PRP samples were treated at a low (1 μM) concentration and then at a high (10 μM)
concentration of ADP. Before and after stimulation with different doses of ADP, levels of CD62P expression and
formation of platelet micro particles (PMPs) were measured using a flow cytometry method.
Results: The platelets from patients with T2DM had higher levels of CD62P expression before any stimulation (P =
0.003) than control samples. Platelets, which underwent the mild stimulation, indicated lower responses to CD62P
expression, but higher PMPs formation after stimulation with high dose of ADP. Patients with T2DM had higher platelet
micro particles in all states with the ADP stimulation. (P = 0.004, SD: ±74.52).
Conclusions: The flow cytometry data indicated that platelets were pre-active and associated with metabolic
conditions in patients with type 2 diabetes mellitus. The induction of desensitization state helped platelets to reduce
the platelet activation and sensitivity to ADP in a diabetic environment. Furthermore, the production of platelets micro-
particles was high in the patients; and desensitized platelets were more susceptible to shedding of micro-particles.
Keywords: Type 2 diabetes, Desensitization, Adenosine diphosphate (ADP), Platelets
Background
Diabetes is a group of metabolic diseases that can be diag-
nosed by Hyperglycemia and is due to impaired insulin se-
cretion, insulin performance, or both [1]. Type 2 diabetes
mellitus (T2DM) is the cause of over 80% of diabetes mel-
litus cases and emerges as a result of genetic and environ-
mental factors. Impaired insulin secretion and reduced
sensitivity to insulin in the liver tissue, skeleton muscles
and fat tissue are main pathophysiological characteristics
of T2DM [2]. Patients with T2DM have higher risk of de-
veloped atherosclerosis. [3]. Hyperglycemia and several
other factors including hypercoagulability, impaired fibrin-
olysis system, impaired endothelial cells, hyperactive plate-
lets and production of platelet micro-particles (PMPs)
contribute in the creation of a pro-thrombotic state in
patients with T2DM. [4, 5]. Several factors are involved in
the effective formation of hyperactive platelets in T2DM
[6, 7] including hyperglycemia, insulin deficiency, insulin
resistance [8], increased systemic inflammation, some
metabolic conditions such as obesity and dyslipidemia,
some cellular disorders such as failure in regulating
calcium metabolism, increasing the oxidative stress, and
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: r.mahmoodiyan@gmail.com
1Department of Hematology and Blood Banking, School of Allied Medical
Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1971653313,
Iran
Full list of author information is available at the end of the article
Mahmoodian et al. BMC Endocrine Disorders           (2019) 19:62 
https://doi.org/10.1186/s12902-019-0391-2
increasing the P2Y12 signaling and the platelet turn-
over [9].
Platelet micro-particles (PMPs) are small cellular frag-
ments within the range of 0.1 to 1 μm that are separated
from the membrane of activated platelets, stressed platelets,
and apoptotic platelets through shedding. They have
phospholipid plasma membrane and inherit a variety of
functional receptors from platelets [10, 11]. These cellular
fragments are considered to be the most abundant blood
micro-particles expressing some pre-coagulant molecules
such as phosphatidyl serine, and can play roles in the blood
hemostasis, thrombosis, cancer and inflammation similar
to platelets [12, 13]. PMPs are involved in thrombotic prob-
lems and cardiovascular complications in T2DM. Coagula-
tion activities of PMPs are 50 to 100 times more than
active platelets; hence, they are considered as potential
targets for the reduction of atherosclerosis development in
diabetes [14].
Desensitization might be generally considered as an
adaptive mechanism that is applied by some kinds of cells
to regulate their responses when they are exposed to con-
tinuous stimulations. Desensitization of platelets can be
diagnosed according to the decline of activation response
of cells and can be regulated by intracellular signaling
mechanisms [15]. After continuous mild stimulation with
endogenous ADP, platelets indicate a declined sensitivity to
be activated by strong ADP stimulations [16]. This
phenomenon can be also observed following long term
treatments with drugs that act as agonist receptors [17].
Desensitization of platelets occurs in vivo after major sur-
geries and may be involved in post-surgery bleeding events.
Desensitization can be also seen in vitro, in particular for
suspended platelets in buffers as a replacement for plasma.
This state is temporary and disappears after enzymatic deg-
radation of the available ADP in the environment [18]. The
ATP/CD39 diphosphohydrolase on the surface of healthy
vessels prevents the activation of platelets under normal
conditions. The function of this enzyme is impaired in clin-
ical conditions that are associated with vascular damages
including diabetes [19]. G-protein dependent ADP recep-
tors, P2Y1 and P2Y12 are involved in the desensitization of
platelets after the long-term interaction with ADP.
Desensitization process is complex and includes the recep-
tor phosphorylation, separation of G-proteins and internal-
ization of receptors [20]. Considering pro-thrombotic
conditions in patients with T2DM, the desensitization of
platelets to the ADP might be an adaptive response pre-
venting major thrombotic events. In the present study,
platelet samples of patients with T2DM were evaluated for
determining the activation responses as well as amount of
PMPs formation after mild and strong ADP stimulations.
Accordingly, we sought to determine whether an increase
in thrombotic events in the patients with type 2 diabetes
was due to an elevation in the sensitivity of platelets to
ADP or because of increased formation of platelet micro
particles.
Methods
Participants
In the present study, 40 patients with T2DM referred to
the central medical laboratory of Kashan, and 35 healthy
volunteers were included after receiving their consent.
All participants were non-smokers, and did not consume
any anti-platelet drugs at least for two weeks. The inclu-
sion criteria of T2DM were as follows: FBS ≥ 126 mg/dl;
OGTT≥200 mg/dl; hemoglobin A1C ≥ 6.5%; and patients
under the medication and insulin therapy. The patients
were asked for fasting and non-use of antiplatelet drugs
before sampling. Renal function was normal in all pa-
tients and they still had no kidney symptoms. Sampling
of participants (both patients with T2DM and healthy
controls) was randomly performed. After participants’
qualification for inclusion criteria, they completed in-
formed consent forms. Table 1 presents general charac-
teristics of T2DM and controls. Ethical approval of
study was obtained from the ethics committee of Shahid
Beheshti University of Medical Sciences.
Blood samples collection and the PRP preparation
The collected blood samples into tubes containing sodium
citrate 3.8% as the anticoagulant were subjected to the soft
centrifugation to obtain the platelet rich plasma (PRP).
Experimental treatments
Platelets in PRP samples were subjected to the mild
stimulation (low dose) with ADP (1 μM) for an hour, or
to the strong stimulation (high dose) with ADP (10 μM)
for 10min or both in a sequential order (Low+ High)
[15, 21]. A sample remained non-stimulated (Resting
Table 1 General characteristics of T2DM and controls
T2DM (n = 40) Control (n = 35)
Age (years) 55.41 ± 7.23 54.61 ± 8.62
Diabetic duration (years) 6.08 ± 2.64 None
Male 22 17
Female 18 18
Fasting Blood sugar (mg/dl, mean) 145 ± 8.0 92 ± 5.0
HbA1c (%, mean) 8.36 ± 2.35 5.47 ± 0.22
OGTT (mg/dl, mean) 275 ± 14.35 170 ± 12.35
Microvascular complications None None
Macro vascular complications None None
Treatment None
Insulin, n (%) 15 None
Oral anti-diabetic agents, n (%) 19 None
Insulin+Oral anti-diabetic agents, n (%) 6 None
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platelets or baseline stage). Paraformaldehyde (PFA) was
added to all platelet samples at a final concentration of
1% to stop the stimulation. The process could lead to
the desensitization of platelets to ADP which was then
verified by the flow cytometric analysis. Four flow
cytometry tubes were considered for each PRP sample in
order to study the impact of each concentration of ADP
on platelets.
Flow cytometry analysis
The flow cytometry analysis of samples was conducted
using CyFlow®Space, Partec GmbH (Germany). Four
tubes were considered for each PRP sample. The first
tube contained resting platelets (Baseline) without add-
ing any ADP. The second tube contained treated plate-
lets at a low concentration of ADP (Low) incubated for
an hour; and the third tube contained treated platelets
in a low dosage of ADP and incubated for an hour, and
then treated with a high dosage of ADP and incubated
for 10 min (Low + High). The forth tube contained
platelets which were only treated at a high concentration
of ADP (High) for 10 min. The flow cytometry measure-
ment was conducted for each stage in two separate
tubes. One for incubation with the CD62P specific anti-
body conjugated with RPI (ABCAM, UK) and the other
containing CD41 specific antibody conjugated with RPI
(DAKO, Germany) and an Annexin-v specific antibody
conjugated with FITC (TREVIGEN, US). Incubation of
samples with antibodies was implemented an hour at the
room temperature with mild shaking. The expression of
CD62P and counting CD41 + -Annexin-v +micro parti-
cles were measured in each tube. The expression of
CD62P was done after gating the platelets in a FSC for
SCC chart, and then analyzed in a histogram chart in FL2
channel (Antibody for CD62P). Isotype controls were used
for each flow cytometry run (Fig. 1). The micro particles
were gated less than a micron in order to gate the platelet
micro particles at the first stage of the FSC and SCC chart,
and then the micro particles were specified considering
the FL1 channel (Antibody against Annexin-v) and FL2
channel (Antibody against CD41)(Fig. 2).
The extent of expression for CD62P was reported
in percentage as the mean fluorescent intensity (MFI);
and the number of measured platelet micro particles
was stated as their number in the microliter. The de-
rived data from the flow cytometry was then analyzed
using Flowjo software (FlowJo 7.6.2, Engine 2.97000.
OS version: Windows 7).
Statistical analysis
The MFI was calculated for a large sample of platelets (20,
000 platelets per samples) for each flow cytometric sam-
ple. SPSS 16.0 was used with a P value < 0.001 in the ex-
pression of CD62P; and P-value < 0.001 in micro particles
was considered significant. According to the Kolmogorov-
Smirnov test, the population distribution was normal at
Fig. 1 Expression of CD62P in histogram charts in FL2 channel (Antibody for CD62P) after gating platelets in a FSC for SCC chart, then analyzing
in a histogram chart in FL2 channel. a, d: Isotype controls were used for each flow cytometry run. b,c: b is a histogram of low-dose ADP
treatment in control; and c is a histogram of Low + High dose ADP treatment in control. e, f: e is a histogram of Low dose ADP treatment in
Diabetes and f is a histogram of Low + High dose ADP treatment in Diabetes
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all stages of treatment with ADP in both healthy people
and the T2DM group (p > 0.05).
Results
The flow cytometry analysis indicated that platelets of pa-
tients with T2DM had a higher expression of CD62P at the
resting stage (baseline), and they expressed a higher level of
CD62P even in the absence of exogenous ADP. In the
second to forth tube of PRP, this increased expression of
CD62P was greater in patients with T2DM in comparison
with healthy participants; and the difference was due to the
pre-activity of platelets at the baseline stage (Fig. 3). Ac-
cording to the comparison of high-dose tubes and High+
Low dose tubes, the mild agonist treatment led to the
lower CD62P induction and reduced reactivity of platelets.
The lower expression of CD62P might be due to the
desensitization phenomenon as a result of mild agonist
stimulation (Fig. 3). The phenomenon played a significant
role in turning off signal transduction pathways in platelets.
This lower reactivity of platelets as a result of mild agonist
stimulation was seen in both groups; however, the reduc-
tion of CD62P expression was higher in patients with
T2DM. Furthermore, the extent of platelets sensitivity and
their irritability to ADP was calculated and reported as the
Fold. The term “Fold” was considered to better show levels
of sensitivity and irritability of platelets relating to ADP. To
this end, the CD62P expression level at each stage of the
agonist treatment was divided by the CD62P expression
level at the baseline (the stage before the start of agonist
treatment) and the resulting number was reported as Fold
and it was accordingly charted (Fig. 4). Sensitivity and irrit-
ability of platelets to ADP were lower in diabetic samples,
but higher in normal samples. In other words, the more
platelets were in rest, the more irritability it had to ADP.
Fig. 2 Platelets mico paticles gating. The micro particles were gated as events less than one micron and then the micro particles were specified
considering the FL1 channel (Antibody against Annexin-v) and FL2 channel (Antibody against CD41)
Fig. 3 Expression of CD62P at experimental stages in Diabetic and non- Diabetic samples. The extent of expression for CD62P was reported in
percent as mean fluorescent intensity (MFI) with a P = value < 0.003. *** P < 0.001 represents significant changes from Non- Diabetic control
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On the other hand, the mild agonist platelet stimulation,
which might cause the desensitization of platelets, led to
the reduced irritability of platelets to ADP.
The number of CD41 + -Annexin-v + platelet micro par-
ticles was separately counted for each tube after the obser-
vation of extent of expression of CD62P for each tube
(Fig. 5). The counted number of platelet micro-particles in
all four tubes was higher for diabetic platelets; and the for-
mation of micro platelets was higher in these patients than
healthy individuals. Micro-particles were also formed in
baseline platelet samples due to the activation of platelets
during the sampling process and preparation stages. How-
ever, there were considerable findings about micro-
particles indicating that the highest rate of formation of
platelet micro-particles belonged to a tube with High+
Low dose ADP rather than a tube with high ADP.
On the contrary to the expectation, the platelets, which
were treated with low dosage of ADP and then with high
dosage of ADP, created more micro particles than ones
that were treated with only high dosage of ADP. There-
fore, despite the fact that platelets, which first had mild
agonist treatment and then were treated with high dosage
of ADP, had lower CD62P induction, they were likely to
create more platelet micro-particles.
Discussion
Given the obtained data from the flow cytometry, it can
be concluded that platelets express higher CD62P levels
in patients with type 2 diabetes mellitus, and are pre-
active at the baseline stage without the hexogen agonist
treatment since the beginning as this state of platelets is
related to the existing metabolic environment in patient
with type 2 diabetes mellitus. Platelets are quite sensitive
and responsive to environmental changes. The rate of
glucose concentration in platelets indicates the rate of
extracellular glucose concentration because glucose is
not dependent on insulin in order to enter platelet [22–
24]. Chronic and long-term hyperglycemia is particularly
recognized as a major factor for the activation of plate-
lets and formation of pre-active platelets in patients with
type 2 diabetes mellitus [25–27]. In the present study,
the treatment of PRPs with mild agonist ADP stimula-
tion led to the lower induction of CD62P expression and
reduced reactivity in both diabetic and control platelets
probably due to the desensitization phenomenon. The
extent of CD62P expression was lower in a tube, which
first had a mild agonist stimulation, and it was then
treated with a high dosage of ADP than a tube which was
solely treated with a high dosage of ADP, and thus it can
be concluded that platelets decreased the response to
agonist under the effect of desensitization phenomenon
that could help platelets that were constantly exposed to
agonist in a diabetes metabolic environment [28]. This re-
duced response is higher among diabetic platelets and
leads to the higher reduction of expression for CD62P. In
the diabetes metabolic environment, platelets are con-
stantly exposed to the produced ADP by platelets that are
activated in such an environment and under hypergly-
cemia. Based on findings of the present research, this
phenomenon is effective for reducing the activation of
platelets in response to ADP. Platelets are pre-active in
the patients with type 2 diabetes mellitus and display the
lower irritability to ADP either in low or high dosages.
This reduction of sensitivity and irritability of diabetic
platelets might be due to the desensitization of diabetic
platelets in diabetic vessels and in constant stimulation by
ADP, thereby leading to the reduced response of platelets
to ADP. However, the sensitivity and irritability of plate-
lets of non-diabetic individuals to ADP are always higher
and express more rates of CD62P throughout the agonist
Fig. 4 The extent of platelets sensitivity and their irritability to ADP. The more the platelets are in resting, the more irritability it has to ADP. The
mild agonist stimulation of the platelets (Low + High ADP) led to reduced irritability of the platelets to ADP. *** P < 0.001 represents significant
changes from Non- Diabetic control
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treatment. The mild agonist stimulation of platelets (for
both groups) led to reduced irritability of platelets to
ADP. According to platelet micro-particles, findings indi-
cated that if platelets, which were already exposed to the
mild agonist stimulation and desensitized under diabetic
vascular conditions, were exposed to high dosage of ADP,
for instance, to a thrombotic clot, they would produce
more amounts of micro-particles. High rate and system-
atic production of platelet micro-particles was considered
as a pro-inflammatory mediator and pathological factor
[29]. Chronic hyperglycemia and pre-active platelets with
high expression rates of CD62P among patients with type
2 diabetes mellitus predisposed the patients to atheroscler-
osis as an important complication among such patients.
There is the evidence for roles of platelets in the athero-
sclerosis, which is intermediated by production of platelet
micro-particles, that can be considered as a prognostic
marker for atherosclerotic cardiovascular diseases such as
diabetes [30, 31]. Study limitations included small sample
sizes and time limit. It is recommended that this study
should be done with a larger sample size in several clinics.
Furthermore, responses of platelets to natural anti-
aggregation material such as PGI2 and NO are reduced
among these patients; and all items of pathogenesis of ath-
erosclerosis are also involved in this disease [32]. Based on
the derived data from this research, the response of plate-
lets and their irritability to ADP indicated a reduction
among patients; and such reduced sensitivity to ADP
along with reduced response to PGI2 and NO might be
according to the occurrence of atherosclerosis in the
patients. Considering structural characteristics and sizes
of platelet micro-particles, their local production made
them strong tools in platelet-cellular communications for
transfer of bioactive molecules with platelet origin such as
growth factors and other signaling molecules and miRNAs
[33]. It occurs if they act as pro-inflammatory mediators
and pathological factors in different pathological situations
when they are systematically and abundantly produced,
thereby leading to the progress of atherosclerosis and
thrombotic complications [34, 35]. According to the re-
search data, the platelets, which had the lower reactivity,
produced more micro-particles. Such micro-particles in a
systematic production brought thrombotic complications;
and the phenomenon might be involved in diabetic com-
plications as well. Diabetic ulcers are the most common
and serious complications of diabetes. Ulcer healing is a
complex biological and dynamic process consisting of four
stages, namely hemostasis, inflammation, proliferation
and remodeling. This process includes various types of
cells, extracellular compounds, growth factors and cyto-
kines all of which are affected by diabetes type 2 diseases
and lead to delayed healing of ulcers [36, 37]. Since the
mild platelet stimulation, which causes developing
desensitization, leads to the reduced reactivity of platelets,
it may be a factor for facilitating such a late healing of dia-
betic ulcers.
Conclusion
Under mild agonist stimulation conditions and despite
the high expression of CD62P, platelets had a low sensi-
tivity to ADP probably due to the desensitization that
helped platelets to adapt to their metabolic environment.
Therefore, such lower reactivity of platelets to ADP
along with reduced sensitivity to PG- I2 and NO could
play roles and be involved in increasing the occurrence
of atherosclerosis among patients with type 2 diabetes
Fig. 5 The number of CD41 + -Annexin-v + platelet micro particles for each tube. The counted number of platelet micro particles in all four tubes
was higher for the diabetic platelets. The platelets, which were treated with a low dosage of ADP and afterwards were treated with High dosage
of ADP, formed more micro particles comparing to ones that were treated with only high dosage of ADP. Despite the fact that platelets, which
first had mild agonist treatment and then were treated with high dosage of ADP actually had lower CD62P induction, they were likely to form
more platelet micro particles. *** P < 0.001 represents significant changes from Non- Diabetic control
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mellitus. On the other hand, platelets were likely to pro-
duce more micro-platelets under the influence of a mild
agonist stimulation that could be involved in thrombotic
complications of diabetes.
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